Renhe Pharmacy Co (SZSE:000650) ROCE %: 12.35% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:000650 Renhe Pharmacy Co Ltd SZSE:000650
83 GF Score
Price ¥5.39
GF Value ¥5.07
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Renhe Pharmacy Co ROCE %?

Renhe Pharmacy Co SZSE:000650 +0.37% 83 ROCE % is 12.35% as of Jun. 2026. GuruFocus rates SZSE:000650 with a GF Score™ of 83/100 and a GF Value™ of ¥5.07 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Renhe Pharmacy Co's annualized ROCE % for the quarter that ended in Jun. 2026 was 12.35%.

Renhe Pharmacy Co  (SZSE:000650) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Renhe Pharmacy Co ROCE % Related Terms

Renhe Pharmacy Co ROCE % Historical Data

* Premium members only.

The historical data trend for Renhe Pharmacy Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renhe Pharmacy Co ROCE % Chart

Renhe Pharmacy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.87 15.37 13.66 11.44 9.62

Renhe Pharmacy Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.12 8.81 2.78 13.76 12.35
SZSE:000650
83GF Score
Renhe Pharmacy Co Ltd SZSE:000650
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renhe Pharmacy Co ROCE % Calculation

Renhe Pharmacy Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=664.984/( ( (7482.46 - 636.345) + (7735.118 - 762.757) )/ 2 )
=664.984/( (6846.115+6972.361)/ 2 )
=664.984/6909.238
=9.62 %

Renhe Pharmacy Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=887.916/( ( (7933.936 - 784.542) + (8156.557 - 928.523) )/ 2 )
=887.916/( ( 7149.394 + 7228.034 )/ 2 )
=887.916/7188.714
=12.35 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.35% mean?
Renhe Pharmacy Co (SZSE:000650) has a ROCE % of 12.35% as of Jun. 2026.
Is Renhe Pharmacy Co's ROCE % too high?
Renhe Pharmacy Co's current ROCE % is 12.35%. The Drug Manufacturers industry median ROCE % is 6.63. Renhe Pharmacy Co's value of 12.35% is 86.3% above this industry median. Overall, Renhe Pharmacy Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Renhe Pharmacy Co's ROCE % compare to ZTS?
Renhe Pharmacy Co's ROCE % of 12.35% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.63. Renhe Pharmacy Co's value of 12.35% is 86.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.63, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renhe Pharmacy Co's current ROCE % of 12.35% is 86.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renhe Pharmacy Co's current ROCE % is 12.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renhe Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Renhe Pharmacy Co (SZSE:000650) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.07, compared to a current price of ¥5.39 — trading 6.3% above its estimated fair value. The current ROCE % is 12.35% and 86.3% above the Drug Manufacturers industry median of 6.63. Renhe Pharmacy Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Renhe Pharmacy Co (SZSE:000650), the current ROCE % is 12.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renhe Pharmacy Co (SZSE:000650) Overvalued in 2026?

Based on GuruFocus' analysis, Renhe Pharmacy Co stock appears to be overvalued. The current stock price of ¥5.39 is trading 6.3% above its estimated GF Value™ of ¥5.07. GuruFocus considers Renhe Pharmacy Co to be Fairly Valued.

Key valuation signals for SZSE:000650:

  • ROCE %: 12.35%
  • GF Value™: ¥5.07 vs. price of ¥5.39 (6.3% above fair value)
  • GF Score™: 83/100 with 1 warning sign
  • Industry Position: 86.3% above the Drug Manufacturers median

No single metric tells the full story. See the SZSE:000650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renhe Pharmacy Co Business Description

Address No. 998 Honggu Middle Avenue, Greenland Central Plaza, 18th Floor, Yuanchuang International, Zone B, Honggutan New District, Jiangxi Province, Nanchang, CHN, 330038
Renhe Pharmacy Co Ltd is a China-based company engaged in the production and sale of Chinese and Western medicines, raw materials, and health-related products, including oral solid dosage forms, oral liquid dosage forms, large-volume injections, small-volume injections, external washes, liniments, suppositories, ointments, and other dosage forms of pharmaceuticals and health-related products. The company's main products include: Renhe Kelike, Youkadan series, Fuyanjie series, Da Huo Luo capsules, Shanliang eye drops, Qinghuo capsules, and Zhengwei capsules.
83GF Score

Get the complete analysis for SZSE:000650

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.39
Price
¥5.07
GF Value